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ABSTRACT  
          The objective of the present study was to develop and 
evaluate mucoadhesive dosage form of Domperidone maleate. It is 
an antiemetic synthetic benzimidazole compound that acts as a 
dopamine D2 receptor antagonist. Mucoadhesive Domperidone 
maleate tablet formulation was prepared by direct compression 
method. The formulation F3 containing (Carbopol 940 + sodium 
alginate) was found to be best among all the formulation batches 
because of its consistent release rate for 7 h and extent of drug 
release was 94.44%. Graphical treatment of the formulation F3 to 
Higuchi’s equation showed that the drug release was diffusion 
mediated. In-vitro permeability study for formulation F3 for 7 h had 
shown 76.69% drug release. FTIR studies showed no evidence on 
interaction between drug and polymers.  
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INTRODUCTION 
The unique environment of the oral 
cavity offers its potential as a site for drug 
delivery because of the rich blood supply and 
direct access to systemic circulation, the oral 
mucosal route is suitable for drugs, which are 
susceptible to acid hydrolysis in the stomach or 
which are extensively metabolized in the liver 
(first-pass effect). Mucoadhesive drug delivery 
system can improve the effectiveness of a drug 
by helping to maintain the drug concentration 
between the effective and toxic levels. The 
advantages of buccal drug delivery sysyem are 
localization of the dosage form in specified 
regions to improve and enhance bioavailability 
of drugs. Drugs that are absorbed through the 
mucosal lining of tissue can enter directly into 
the blood stream and not be inactivated by 
enzymatic degradation in the gastrointestinal 
(GI) tract. Inhibiting the dilution of the drug in 
the body fluids and allowing targeting of drug 
at specific site. Mucoadhesive drug delivery 
system utilize the property of bioadhesion of 
certain water soluble polymers which become 
adhesive on hydration and hence can be used 
for targeting a drug to a particular region of the 
body for extended period of time (Rodriguez et 
al., 2000; Teweset al., 2006; Hilleryet al., 2001; 
Gavaskar et al., 2010). 
 
Domperidone maleate is a synthetic 
benzimidazole compound that act as a 
dopamine receptor antagonist. Its localization 
outside the blood brain barrier and antiemetic 
properties has made it a useful adjunct in the 
therapy for Parkinsonism disease. Domperi-
done maleate undergoes first-pass and gut wall 
metabolism. Through hydroxylation and 
oxidative N-dealkylation, domperidone is 
metabolized to hydroxyl domperidone and 2, 3- 
dihydro-2-oxo-1-H-benizimidazole-1-Propionic 
acid respectively. The systemic bioavailability of 
Domperidone maleate is 15% following oral 
administration as it extensively metabolized in 
liver. The low bioavailability is due to the first-
pass hepatic and intestinal metabolism 
(Martindale and Sweetman, 2002; Indian 
Pharmacopoeia, 2007). 
Therefore, the objective of present study 
was to prolong the drug plasma half-life and 
avoid first- pass hepatic metabolism of 
Domperidone maleate by formulating 
Mucoadhesive dosage form.  
 
METHODOLOGY 
Materials 
Domeperidone maleate was obtained as 
a gift sample from Vasudha Pharma Chemical, 
Hyderabad. Carbapol-940 was obtained as a gift  
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sample from SD Fine Chemicals Ltd. Mumbai. 
Sodium alginate, HPMC-K4M, SCMC, 
Magnesium stearate were purchased from Otto 
Chem. Ltd. Mumbai and Sodium hydroxide, 
Potassium dihydrogen phosphate were 
procured from Qualigens Fine Chemicals, New 
Mumbai. All other excipients used in the study 
were of Analytical reagent grade. 
 
Formulation of mucoadhesive buccal 
tablet 
Domperidone maleate tablets 
formulations were prepared by direct 
compression using a concave faced single 
punch tableting machine. Each tablet contained 
a constant amount of Domperidone maleate 
(20 mg) and Magnesium stearate (1 mg) and 
varying composition of buccal bioadhesive 
polymer mixture of Carbopol 940 and Sodium 
alginate or carbopol 940 and HPMC-K4M or 
Carbopol 940 and SCMC. 
Accurately weighed quantities of 
polymers are homogenously mixed with 
Domperidone maleate. Then Magnesium 
stearate was added in it and mixed continuously 
for 10 min. The machine was adjusted to 
produce tablets of approximate weight of 150 
mg. Composition of formulation batches 
containing different polymers (mgs) are given 
in table I. 
 
Evaluation of physico-chemical proper-
ties 
Weight variation test 
Twenty tablets were selected at random, 
individually weighed in a single pan electronic 
balance and the average weight was calculated. 
The uniformity of the weight was determined 
according to USP specification Menon et al., 
2011. 
 
Thickness 
The thickness of a tablet is only 
dimensional variable related to the compression 
process. The thickness of tablets was carried 
out using Vernier calliper (Menon et al., 2011). 
 
Hardness test 
The Monsanto hardness tester was used 
to measure the hardness of tablets. Five tablets 
from each batch were used for hardness test 
and results were expressed in kg/cm2 (Menon et 
al., 2011) 
 
Friability test 
Friability Test was performed in Roche 
type Friabilator apparatus, where the tablets 
were subjected to the combined effect of 
abrasion and shock by utilizing a plastic 
chamber that revolves at 25 rpm, dropping the 
tablets at a distance of six inches with each 
revolution. The tablets are then dusted and 
reweighed.8  
 
Drug content 
Accurately weighed quantity of tablet 
powder equivalent to 100 mg of the drug was 
transferred into a 100 mL volumetric flask. 
Phosphate buffer pH 6.8 was added in it to 
make up the volume upto 100 mL. The 
resulting solution was sonicated for 5 min and 
then filtered through 0.45  filter paper. 
Dilutions were made with phosphate buffer pH 
6.8 to obtain a solution containing 50 g/mL 
of the drug. The drug content was determined 
by measuring the absorbance of the resulting 
solution spectrophotometrically at 284 nm. 
 
Surface pH 
The surface pH of the tablets was 
determined in order to investigate the 
possibility of any side effects, in vivo. As an 
acidic or alkaline pH may cause irritation to the 
buccal mucosa, it was our attempt to keep the 
surface pH as close to neutral as possible. The 
tablets were allowed to swell by keeping then in 
contact to 1.0 mL of distilled water for 2 h in 
specially fabricated glass tube. The surface pH 
was noted bringing the electrode in contact 
with the surface of the tablet and allowing it to 
equilibrate for 1 min (Miyazaki et al., 1995). 
 
In-vitro swelling studies 
Domperidone maleate buccal (n=7) 
tablets from each formulations were weight 
individually (designed as W1) and placed 
separately in petri dishes containing 4 mL of 
phosphate buffer (6.8) solution. At regular 
intervals (1, 2, 3, 4, 5, 6 and 7 h), the tablets 
were removed from the petridish and excess 
surface water was removed carefully using the 
filter paper. The swollen tablets were then 
reweighed (W2) and swelling index (SI) was 
calculated using the formula (Kasshapa et al., 
2004). 
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1W2WSI

  
Where, 
SI  = Swelling Index 
W2 = Weight of tablet after swelling 
W1 = Weight of tablet before swelling 
 
In-vitro mucoadhesion strength 
Mucoadhesion strength of tablet was 
measured with porcine buccal mucosa using a 
modified 2-arm balance. Porcine buccal mucosa 
was obtained from a local slaughter house and 
stored in phosphate buffer pH 6.8 upon 
collection. The experiments were performed 
within 3 h of procurement of the mucosa. The 
porcine buccal mucosa was fixed to the 
stainless steel piece with cynoacrylate adhesive 
and then placed in a beaker. Phosphate buffer 
pH 6.8 was added into the beaker up to the 
upper surface of the buccal mucosa to maintain 
buccal mucosal viability during the 
experiments. The tablet was attached to the 
upper clamp of the apparatus and then the 
beaker was raised slowly until contact between 
porcine buccal mucosa and tablet was 
established. A preload of 50 g was placed on 
the clamp for 5 min (preload time) to establish 
adhesion bonding between tablet and porcine 
buccal mucosa. The preload and preload time 
were kept constant for all the formulation. 
After completion of the preload time, preload 
was removed from the clamp and water was 
then added in the beaker from the burette at a 
constant rate of 100 drops/min. The addition 
of water was stopped when tablet was detached 
from porcine buccal mucosa. The weight of 
water required to detach tablet from buccal 
mucosa was noted as mucoadhesive strength, 
and these experiments were repeated with fresh 
mucosa in an identical manner (Kasshapa et al., 
2004; Emami et al., 2008). 
 
Drug-polymer interaction study 
The FTIR technique was used for the 
identification of pure drug Domperidone 
maleate and various polymers like Carbopol 
940, Sodium alginate, Hydroxypropyl methyl-
cellulose K4M, Sodium carboxy methylcellulose  
and best formulation batch F3, containing 
physical mixture were identified and  determine  
to check the interaction of drug and the 
polymer in the formulation by using Perkin 
Elmer Furrier transform infrared spectrometer 
by KBr pellets (Disc Method). 
 
In-vitro drug release studies 
In-vitro drug release study of 
mucoadhesive tablets of Domperidone maleate 
was carried out using USP type I apparatus 
(Paddle method) at 50 rpm. Medium used for 
release rate study was 500 mL phosphate buffer 
solution pH 6.8. The assembly was maintained 
at 37±0.5º C during the course of study. 5 mL 
sample was withdrawn, at regular time interval 
of 1 h upto 7 h and replaced with 5 mL of fresh 
dissolution medium. The amount of drug 
released was determined by spectrophoto-
metrically at 284 nm (Nakhat et al., 2008; Singh 
et al., 2006). 
 
In-vitro drug permeation studies 
Only the mucoadhesive tablets, which gave the 
optimum release in 7 h and appropriate 
mucoadhesive strength, were subjected to the 
permeation studies. The permeation of 
Domperidone maleate through porcine buccal 
membrane was carried out using modified 
diffusion cell. The membrane was mounted 
over a diffusion cell of diameter 2.1 cm and 
selected matrix tablet placed on the membrane. 
The membrane were placed between the donar 
compartment containing 4 mL of 6.8 pH buffer 
and receptor compartment 15 mL of 6.8 pH 
buffer, entire surface of membrane was in 
contact with receptor compartment was 
agitated with magnetic stirred at approximately 
150 rpm and temperature was maintained at 
37°. Each sample of 5 mL were withdrawn 
from the beaker at 1, 2, 3, 4, 5, 6 and 7 h 
intervals and replaced by equal volumes of 
fresh 6.8 pH buffer. The concentration of 
Domperidone maleate in the samples was 
measured spectrophotometrically at 284 nm 
(Yamsani et al., 2007; EL-samaligy et al., 2010; 
Javier et al., 2011; Bayrak et al., 2011). 
 
In-vivo human acceptability studies 
The study was conducted on 10 healthy 
human male volunteers (aged 18-55 years) 
under the medical supervision of a team of 
physician and  the  informed consent was taken 
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from all volunteers before conducting the 
study. Food was prohibited from 0.5 h before 
the study until its conclusion. Volunteers were 
given mucoadhesive tablet and instructed to 
press the tablet against the buccal mucosa for         
1 min. A questionnaire was given, to volunteers 
to score the parameters such as irritancy, 
comfort,  taste, dry mouth, salivation and 
dislodgement of the tablet during the study and  
 
 
 
 
heaviness of the system at the place of 
attachment (Kasshapa et al., 2004).  
 
Drug release kinetics for the various 
formulation batches 
The in-vitro drug release data of 
Domperidone maleate mucoadhesive tablets 
for all formulation were proceeds for regression 
analysis by using MS-excel statistical function. 
 
Table I. Composition of formulation batches containing different polymers (mgs) 
 
Formulation code F1 F2 F3 F4 F5 F6 F7 F8 F9 
Domperidone maleate 20 20 20 20 20 20 20 20 20 
Carbopol 940 90 80 70  90 80 70 90 80 70 
Sodium alginate 39 49 59 - - - - - - 
HPMC- K4M - - - 39 49 59 - - - 
SCMC - - - - - - 39 49 59 
Magnesium stearate 1 1 1 1 1 1 1 1 1 
Total weight  150 150 150 150 150 150 150 150 150 
 
Table II. Results of physico-chemical properties of tablets 
 
Formula
tion 
batches 
Weight 
uniformity 
(mg)±SD 
Thick
ness 
(mm)
±SD 
Hardne
ss 
(Kg/c
m2) 
Friabil
ity 
(%) 
Drug 
cont
ent 
(%) 
Surfa
ce 
pH 
Swellin
g 
index 
in  (7h) 
Muccoad
hesive 
strength 
(gms) 
F1 150.8±0.78 
3.10±0.
06 
4.5 0.56 98.88 6.2 3.072 48.36 
F2 150.8±0.78 
3.10±0.
06 
4.0 0.59 98.57 6.8 2.559 45.20 
F3 151.1±0.92 
3.11±0.
02 
3.5 0.79 99.62 6.9 2.433 41.09 
F4 150.5±0.91 
3.12±0.
02 
4.5 0.45 98.51 6.5 3.673 49.32 
F5 151.5±0.81 
3.12±0.
02 
4.5 0.59 99.25 6.7 3.205 42.20 
F6 152.0±1.96 
3.12±0.
02 
4.0 0.75 98.56 7.1 2.933 40.13 
F7 152.6±2.21 
3.13±0.
04 
4.5 0.45 98.85 6.9 3.403 43.18 
F8 151.3±1.19 
3.13±0.
08 
4.0 0.53 98.69 7.2 2.673 37.25 
F9 151.2±1.08 
3.16±0.
04 
4.0 0.70 99.24 7.3 2.202 35.64 
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RESULTS AND DISCUSSION 
Physico-chemical properties 
All the formulations were varied from 
150.8 to 152.6 mg with minimum standard 
deviation values indicate that the uniform 
distribution of polymer and drug in the tablets. 
The tablets varied from 3.10 to 3.16 mm in 
thickness with minimum standard deviation 
values; it assumed that the tablets show 
uniformity in thickness. The hardness of the 
tablets was found to be 3.5 to 4.5 kg/cm2. The 
hardness  is  slightly  lower than that of the oral  
tablets; this will be aid in the better absorption 
of moisture and swelling. Handling will not 
affect the tablet integrity. The hardness of 
mucoadhesive tablets varied although 
compression force was constant. This may                
be due to the increased concentration of              
the polymer in the formulations. The friability 
of the tablets was found to be 0.45 to 0.79 %. 
Friability was found to inversely proportional 
to the polymer concentration. This may be due 
to the more adhesive property of carbopol 940. 
Drug content in the tablets were within the 
limit of 98.51 to 99.62 %. As an acidic or 
alkaline surface pH may cause irritation to the 
buccal mucosa, the buccal tablets are 
formulated to have surface pH as close to 
neutral as possible within salivary pH. The 
surface pH of all the formulations was close to 
neutral pH and hence, these formulations may 
not cause any irritation in the buccal cavity. The 
formulations containing higher amount of 
Carbopol-940 showed higher pH because 
carbopol 940 is acidic in nature. Appropriate 
swelling behavior of a mucoadhesive tablet              
is the essential property for uniform                    
and   prolonged   release  of  drug  and effective  
mucoadhesion. The swelling index was higher 
in formulation F4 i.e 3.673 in 7 h. The 
formulation having higher amount of carbopol 
940 shows more swelling index, this may be 
due to more hydrophilic nature of Carbopol 
940. The mucoadhesive strength of the 
formulations was found to be a function of the 
concentration of the polymer. Among the 
formulations, those containing higher 
concentration of Carbopol 940 exhibited 
maximum mucoadhesive strength. The 
mucoadhesive strength of formulation  F4  was  
Table III. Result of In-vitro drug release studies 
 
Sr. No Formulation code Cumulative % drug release in 7 h 
1 F1 76.85 
2 F2 87.03 
3 F3 94.44 
4 F4 57.40 
5 F5 65.74 
6 F6 72.22 
7 F7 69.44 
8 F8 73.14 
9 F9 86.11 
 
Table IV. Result of In-vitro permeation study 
 
Sr. No Time (h) Cumulative % drug release 
1 0 0 
2 1 10.83 
3 2 19.47 
4 3 27.52 
5 4 39.33 
6 5 49.50 
7 6 62.36 
8 7 76.69 
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higher (49.32 gms) and less in F9 (35.64 gms). 
Wetting, interpenetration, and mechanical 
interlocking between mucus and polymer are 
the successive stages of mucoadhesion. The 
strength of mucoadhesion is affected by various 
factors such as molecular weight of polymers, 
contact time with mucus, swelling rate of the 
polymer,  and the biological membrane used  in  
the study. The higher mucoadhesion of 
carbopol 940 and HPMC-K4M (F4, F5 and F6) 
may be due to the ionization of carbopol 940 at 
salivary pH which leads to improved 
attachment of the device to mucosal surface. 
The superior quality of Carbopol 940 as 
bioadhesive polymer as compared to HPMC 
K4M and SCMC has also been revealed in 
other studies. The results of physico-chemical 
evaluation of Domperidone maleate muco-
adhesive tablets are tabulated in table II. 
 
Table V. Response of healthy human male volunteers to various parameters 
 
Sr. No. Criteria Volunteer’s response (%) 
1 Irritation  
a) None 
b) Slight 
c) Moderate 
d) Severe 
 
100 
- 
- 
- 
2 Taste 
a) Normal 
b) Slightly unpleasant 
c) Very unpleasant  
d) Pleasant 
e) Very pleasant  
 
70 
30 
- 
- 
- 
3 Comfort 
a) Very comfortable 
b) Comfortable 
c) Slightly uncomfortable 
d) Moderately uncomfortable 
e) Severely uncomfortable 
 
- 
70 
30 
- 
- 
4 Dryness of mouth 
a) None 
b) Slight 
c) Moderate 
d) Severe 
 
80 
10 
10 
- 
5 Salivary secretion  
a) None 
b) Slight 
c) Moderate 
d) Severe 
 
10 
80 
10 
- 
6 Heaviness of tablet at the place of 
attachment  
a) None 
b) Slight 
c) Moderate 
d) Severe 
 
 
90 
10 
- 
- 
7 Dislodgement of the system during study 
a) No 
b) Yes 
 
100 
- 
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In-vitro drug release 
The formulation F1, F2, F3, F4, F5, F6, 
F7, F8 and F9 showed 76.85%, 87.03%, 
94.44%, 57.40%, 65.74%, 72.22%, 69.44%, 
73.14%, and 86.11% drug release respectively. 
The maximum drug release was shown by 
formulation F3. The releases of drug from the 
tablets were depending on the proportion of 
the carbopol 940. The release rate  is  decreased  
with increasing the polymer concentration 
Carbopol 940, indicating the retardant effect of 
the polymer carbopol 940 on the drug release. 
Among the nine formulations the F3 shows 
maximum drug release i.e. 94.44%, due to high 
concentration of sodium alginate. According to 
the graph of square root of Time Vs 
Cumulative % drug release was maximum from 
formulation F4 i.e. 99.84 fallow matrix 
diffusion. The results of In-vitro drug release are 
shown in table III. 
In-vitro permeation study 
The in-vitro permeation study was carried 
for formulation F3 on porcine buccal mucosa. 
The in-vitro drug permeation was 76.69% for 7 
h. The in-vitro drug permeation data further 
proceed for regression coefficient using MS-
excel statistical program. The R2 value for 
formulation F3 was 99.63 it shows zero order 
release. According to the Higuchis plot all the 
formulation shows matrix diffusion drug 
release pattern. 
 
Drug -polymer interaction study 
IR spectral studies for the identification 
of pure Domperidone maleate, Carbopol 940, 
Sodium alginate, HPMC-K4M, SCMC and 
optimum physical mixture of F3 (Domperidone 
maleate + Carbopol 940+ Sodium alginate ) 
shows no interaction between them, it indicate 
that the drug is compactable with polymer it 
gives better formulation hence it was formulate. 
 
In-Vivo human acceptability studies 
Comfortability of the mucoadhesive 
system in the oral cavity is an important 
concern in the buccal drug delivery. Based on 
the results it can conclude that the 
mucoadhesive tablet of Domperidone maleate 
would be comfortably placed in the human oral 
cavity. 
 
Drug release kinetics 
Graphical treatment of the formulation 
F3 to Higuchi’s equation has shown the drug 
release was diffusion mediated (Table VI). 
 
CONCLUSION 
The formulation F3 containing 
(Carbopol 940+sodium alginate) was found to 
be best among all the formulation batches 
because of its consistent release rate for 7 h and 
extent of drug release was 94.44%. Graphical 
treatment of the formulation F3 to Higuchis 
equation has shown the drug release was 
diffusion mediated. In-vitro permeability study 
for formulation F3 for 7 h has shown drug 
release 76.69%. Comfortability of the 
mucoadhesive system in the oral cavity is an 
important concern in the buccal drug delivery. 
Based on the results it can conclude that the 
mucoadhesive tablets of Domperidone maleate 
would be comfortably placed in the human oral 
Table IV. Drug release kinetics for the various formulation batches 
 
Formulation code In-vitro drug release 
Zero order drug 
release 
Higuchis regression 
F1 76.85 0.9957 0.9535 
F2 87.30 0.97.95 0.9919 
F3 94.44 0.9498 0.9928 
F4 57.40 0.9592 0.9984 
F5 65.74 0.9318 0.9962 
F6 72.22 0.9522 0.9958 
F7 69.44 0.9917 0.9565 
F8 73.14 0.9800 0.9561 
F9 86.11 0.9931 0.9687 
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cavity. Hence the formulation F3 achieved the 
objectives of the present study as avoiding first 
pass metabolism, reduced the side effect due to 
the higher dosing frequency, Prolong the drug 
plasma half-life and improve the patient 
compliance. 
As extension of the work for 
pharmacokinetic studies, in-vivo studies on 
animal and controlled clinical studies on human 
being can be carried out in the future. 
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